Abiraterone
- Generic Name
- Abiraterone
- Brand Names
- Yonsa, Zytiga, Abiraterone Krka, Abiraterone Accord, Abiraterone Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C24H31NO
- CAS Number
- 154229-19-3
- Unique Ingredient Identifier
- G819A456D0
- Background
Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis. Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resis...
- Indication
Abiraterone is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in combination with methylprednisolone or prednisone.
...
- Associated Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Associated Therapies
- -
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)
- Conditions
- Interventions
- First Posted Date
- 2021-12-29
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 108
- Registration Number
- NCT05171816
- Locations
- 🇨🇳
Research Site, Zhejiang, China
The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation
- Conditions
- Interventions
- First Posted Date
- 2021-12-22
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- Hongqian Guo
- Target Recruit Count
- 30
- Registration Number
- NCT05167175
- Locations
- 🇨🇳
Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Nanjing, Jiangsu, China
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
- First Posted Date
- 2021-10-20
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Biosplice Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05084859
- Locations
- 🇺🇸
Duke Cancer Institute (DCI) - Duke Cancer Center, Durham, North Carolina, United States
🇺🇸UT Health San Antonio - Mays Cancer Center - Institute for Drug Development, San Antonio, Texas, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 200
- Registration Number
- NCT04947254
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase 1 Study of ATRS-2002 in Healthy Male Adults
- Conditions
- Interventions
- First Posted Date
- 2021-05-10
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Syneos Health
- Registration Number
- NCT04879589
The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC
- Conditions
- Interventions
- First Posted Date
- 2021-04-09
- Last Posted Date
- 2021-04-09
- Lead Sponsor
- Jiangnan University
- Target Recruit Count
- 50
- Registration Number
- NCT04839055
- Locations
- 🇨🇳
Jiangnan University, Wuxi, Jiangsu, China
Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT04748042
- Locations
- 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate
- Conditions
- Interventions
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2021-02-08
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT04736108
- Locations
- 🇨🇳
West China Hospital, Chengdu, Sichuan, China
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-02-02
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 70
- Registration Number
- NCT04734730
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 52
- Registration Number
- NCT04726332
- Locations
- 🇺🇸
Exelixis Clinical Site #2, Dallas, Texas, United States
🇺🇸Exelixis Clinical Site #4, Atlanta, Georgia, United States
🇺🇸Exelixis Clinical Site #3, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.